medigraphic.com
Patología Revista Latinoamericana

2009, Number 1

<< Back Next >>

Patol Rev Latinoam 2009; 47 (1)

Diagnóstico histopatológico e inmunohistoquímico del linfoma de Hodgkin y su diagnóstico diferencial

Lara-Torres C, Ortiz-Hidalgo C

Language: Spanish
References: 55
Page: 35-45
PDF size: 242.48 Kb.


ABSTRACT

Current classification of Hodgkin’s lymphoma is based on that proposed by Lukes and Butker in 1966; it has had little changes since then. Classical Hodgkin’s lymphoma diagnosis requires the identifi cation of Reed-Sternberg cells in the proper cell environment and with own immunohistochemical characteristics; that is, Reed-Sternberg’s cells positive to CD30, CD15 and negative to CD45 and EMA, and sometimes positive to B marker. Immunomarking, besides helping to exactly diagnose of Hodgkin’s lymphoma, has contributed to differentiate it from several entities which it may be confused with since the histological point of view, such as peripheral T lymphoma, T cell-rich/hystiocyterich lymphoma B, mediastinal primary B large cell lymphoma, large cell anaplastic lymphoma, reactive lymphadenopathy of viral origin (infectious mononucleosis), metastasis (melanoma, germinal cell tumor and some sarcomas).


REFERENCES

  1. Ortiz-Hidalgo C. A short history of Hodgkin’s disease and Burkitt’s lymphoma. Am J Clin Pathol 1994;10 (Suppl. 1):S27- S33.

  2. Forteza J. Hematopathology; a leap forward in pathology. A personal view. Sem Diag Pathol 2008;25:166-77.

  3. Taylor CR. A History of the Reed- Sternberg cell. Biomedicine 1978; 28; 96-203.

  4. Stein H. Introduction. Hodgkin Lymphoma. In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumours of haematopoietic and lymphoid tissue. IARC, Lyon 2008; p:321.

  5. Taylor CR. Hodgkin’s disease is a non-Hodgkin lymphoma. Hum Pathol 2005;36:1-4.

  6. Butler JJ. The histological diagnosis of Hodgkin’s disease. Sem Diag Pathol 1992;9:252-6.

  7. Poppema S, Delsol G, Pilieri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma.In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumours of haematopoietic and lymphoid tissue. IARC, Lyon 2008; 323- 5.

  8. Stein H, Delsol G, Pilieri SA. Weiss LM, Popema S, Jaffe ES. Classical Hodgkin Lymphoma. Introduction In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumors of hematopoietic and lymphoid tissue. IARC, Lyon 2008; pp:326-9.

  9. Fung HC, Nademanee AP. Approach to Hodgkin’s lymphoma in the new millennium. Hematol Oncol 2002;20;1-15.

  10. Harris NL, Jaffe ES, Stein H et al. A revised European- American classifi cation of lymphoid neoplasms; A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.

  11. Schmitz KR, Distler V, Renné C, Bräuninger A, Hansmann ML. Pathogenesis of Hodgkin’s lymphoma. Eur J Haematol 2005;75;26-33.

  12. Quintanilla-Martinez L, Gamboa-Domínguez A, Gamez-Ledesma I, Ángeles-Ángeles A, Mohar A. Association of Epstein Barr virus latent membrane protein and Hodgkin’s disease in Mexico. Mod Pathol 1995;8:675-9.

  13. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 2008;132:441-61.

  14. Pilieri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Path 2002;55;162-76.

  15. Gruss H-J, Pinto A, Duyster J, Popemma S, Herrman F. Hodgkin’s disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18;156-63.

  16. Hus S-M, Waldron Jr. JW, Hus P-L, Hough Jr. AJ. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 1993;24:1040-57.

  17. Stein H, Hummel M. Hodgkin’s disease biology and origin of Hodgkin and Reed-Sternberg cells. Cancer Treat Rev 1999;25;161-8.

  18. Hudson MM, Donaldson SS. Hodgkin’s disease. Pediatr Oncol 1997;44;891-906.

  19. Strickler JG, Michie SA, Waranke RA Dorfman RF. The “syncycial variant” of nodular sclerosing Hodgkin’s disease. Am J Surg Pathol 1986;10;170-7.

  20. Van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, et al. Disappearance of prognostic signifi cance of histopathological grading of nodular sclerosing Hodgkin’s disease for unselected patients. Br J Haematol 1997;69;322-7.

  21. Doggett RS, Colby TV, Dorfman RA. Interfollicular Hodgkin’s disease. A. J Surg Pathol 1983;78:22-28.

  22. Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG. Follicular Hodgkin’s disease. Am J Surg Pathol 1995;19:1294-9.

  23. Fraga M, Forteza J. Diagnosis of Hodgkin’s disease; an update of histological and immunophenotypical features. Histol Histopathol 2007;22:923-35.

  24. Sextro M, Diehl V, Franklin J,, et al. Lymphocyte predominanceHodgkin’s disease-A workshop report. European Task Force on Lymphoma Ann Oncol 1996;7:61-65.

  25. Harris NL. The many faces of Hodgkin’s disease around the world; what have we learned from its pathology. Ann Oncol 1998;9:S45-S56.

  26. Rahemtullah A, Lee Harris N, Dorn ME, Preffer FI, Hasserjian RP. Beyond the lymphocyte predominant cell: CD4+CD8+ Tcells in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 2008;49:1870-8.

  27. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-Clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res 2008 Apr 23. [Epub ahead of print].

  28. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707-22.

  29. Poppema S. Lymphocyte-predominance Hodgkin’s disease. Sem Diag Pathol 1992;9;257-64.

  30. Von Wasielewski R, Mengel M, Fischer R, Hansmann M-L, et al. Classical Hodgkin’s disease. Clinical impact of the Immunophenotype. Am J Pathol 1997;151:1123-30.

  31. Horie R, Watanabe T. CD30 expression and function in health and disease. Immunology 1998;10;457-70.

  32. Aber DA, Weiss LM. CD15: A review. Appl Immunohistochem 1993;1;17-30.

  33. Delsol G, Megetto F, Brousset P, et al. Relation of follicular dendritic cells to Reed-Sternberg cells of Hodgkin’s disease with emphasis on the expression of CD21 antigen. Am J Pathol 1993;142:1729-38.

  34. Unger PD, Strauchen JA. Hodgkin’s disease in AIDS patients. Cancer 1986;58;821-5.

  35. Weiss LM, Chang KL. Association of the Epstein-Barr virus with hematolymphoid neoplasia Adv Anat Pathol 1996;3:1-15.

  36. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.

  37. Marish A, Weisenberger D, Duggan M, et al. Epstein-Barr viral genome in lymph nodes from patients with Hodgkin’s disease may not be specifi c to Reed-Sternberg cells. Am J Pathol 1991;139:37-43.

  38. Vose JM. Peripheral T-cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008;22:997-1005.

  39. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fi ndings and clinical outcomes. J Clin Oncol 2008;26:4124-30.

  40. El Weshi A, Akhtar S, Mourad WA, et al. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma 2007;48:1764-73.

  41. Leoncini L, Delsol G, Gascoyne RD, Harris NL, Pilieri M, Stein H. Aggressive B-cell lymphomas; a review based on the Workshop of the XI Meeting of the European Association for Hematopathology. Histopathol 2005;46;241-55.

  42. Ramsey AD, Smith WJ, Isaacson PG. T-cell-rich-B-cell lymphoma Am J Surg Pathol 1988;12:433-43.

  43. Nam-Cha SH, Roncador G, Sánchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte- predominant Hodgkin lymphoma. Am J Surg Pathol 2008;32:1252-7.

  44. De Leval L, Ferry J, Falini B Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal B-cell lymphoma. Evidence for derivation from germinal center B cell?. Am J Surg Pathol 2001;25;1277-82.

  45. Isaacson PG, Norton AJ, Addis BJ. The human thymus contains a novel population of B lymphocytes. Lancet 1987; 2:1488- 91.

  46. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45:619-24.

  47. Savage KJ, Harris NL, Vose JM, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specifi ed: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504.

  48. Vassallo J, Lamant L, Brugieres L, et al. Alk-positive anaplasticlarge cell lymphoma mimicking nodular sclerosis Hodgkin’s disease. Report of 10 cases. Am J Surg Pathol 2006;30:223- 9.

  49. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006;1:375-404.

  50. Vetsika EK, Callan M. Infectious mononucleosis and Epstein- Barr virus. Expert Rev Mol Med 2004;6:1-16.

  51. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003;40:116-23.

  52. Kapatai G, Murray P. Contributions of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphomas. J Clin Pathol 2007;60:1342-9.

  53. Khalidi HS, Singleton TP, Weiss SW. Infl ammatory malignant fi brous histiocytoma: distinction form Hodgkin’s disease and non-Hodgkin’s lymphoma by panel of leukocyte markers. Mod Pathol 1997;10:438-44.

  54. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-60.

  55. Jaffe ES, Zarate-Osorno A, Medeiros LJ. The interrelationship of Hodgkin’s disease and Non-Hodgkin’s lymphomas –Lessons learned from composite and sequential malignancies. Sem Diag Pathol 1992;9:297-303.




2020     |     www.medigraphic.com